Scarica l'app Stockscreener
0.9807
0.79%
0.0077
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.973
Aprire:
$1
Volume 24 ore:
284.59K
Relative Volume:
0.39
Capitalizzazione di mercato:
$54.74M
Reddito:
-
Utile/perdita netta:
$-34.50M
Rapporto P/E:
-1.3116
EPS:
-0.7477
Flusso di cassa netto:
$-27.75M
1 W Prestazione:
+8.91%
1M Prestazione:
+61.75%
6M Prestazione:
+4.88%
1 anno Prestazione:
-26.26%
Intervallo 1D:
$0.963
$1.02
Intervallo di 1 settimana:
$0.88
$1.16
Portata 52W:
$0.5068
$1.915
Pds Biotechnology Corp Stock (PDSB) Company Profile
Nome
Pds Biotechnology Corp
Settore
Industria
Telefono
800-208-3343
Indirizzo
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
0.9807 | 54.74M | 0 | -34.50M | -27.75M | -0.7477 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-01 | Iniziato | B. Riley Securities | Buy |
| 2021-06-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-09 | Iniziato | Noble Capital Markets | Outperform |
| 2019-10-24 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Pds Biotechnology Corp Borsa (PDSB) Ultime notizie
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April - MarketBeat
[EFFECT] PDS Biotechnology Corp SEC Filing - Stock Titan
PDS Biotech 2025 Executive Compensation, Leadership Structure, and Equity Ownership Overview - Minichart
[10-K/A] PDS Biotechnology Corp Amends Annual Report - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) registers $200M shelf, removes $20M ATM - Stock Titan
PDS Biotechnology: FDA-Alignment für VERSATILE-003 - Börse Global
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment - MSN
PDSB Stock Price, Quote & Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology updates corporate presentation highlighting Phase 3 VERSATILE-003, 39.3m mOS and upcoming catalysts - TradingView
PDS Biotech (NASDAQ: PDSB) spotlights PDS0101 Phase 3 and IL-12 ADC - Stock Titan
PDS (PDSB) Stock Analysis: Buy or Sell? | PDS Biotechnology Corporation posts 24.4% EPS beatConsensus Forecast - Cổng thông tin điện tử tỉnh Lào Cai
Form DEF 14AOther definitive proxy statements - ADVFN
PDSB: Positive Data from Phase 2 Trial of PDS01ADC Published - GuruFocus
PDSB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15.00 - GuruFocus
PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright - MarketBeat
Why Is PDS Biotechnology Stock Gaining Wednesday?PDS Biotechnology (NASDAQ:PDSB) - Benzinga
PDS Biotech’s PDS01ADC Shows 78% Response Rate in Phase 2 Metastatic Colorectal Cancer Trial, Published in JCO Oncology Advances - Minichart
PDS Biotech reports 78% response rate in colorectal cancer trial - Investing.com
PDS Biotech reports 78% response rate in colorectal cancer trial By Investing.com - Investing.com South Africa
Interim PDS01ADC data lift responses in tough mCRC for PDS Biotech (PDSB) - Stock Titan
PDS Biotechnology Announces Promising Phase 2 Trial Results of PDS01ADC for Treatment of Colorectal Liver Metastases - Quiver Quantitative
In a 9-patient colon cancer study, PDS drug showed 78% response - Stock Titan
Aug Drivers: Is PDS Biotechnology Corporation trading at a discount2026 Earnings Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Is PDS (PDSB) Stock Expanding | Price at $1.09, Up 0.93%Retail Trader Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Is PDS (PDSB) Stock Declining | Price at $0.76, Up 19.06%Retail Trader Ideas - Xã Vĩnh Công
What is HC Wainwright’s Estimate for PDSB FY2026 Earnings? - Defense World
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript - Insider Monkey
PDSB Should I Buy - intellectia.ai
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
PDS Biotechnology Corp 2025 Annual Report: Versamune® Immunotherapy Pipeline, Clinical Results, and Executive Leadership Overview - Minichart
PDS Biotech amends phase 3 trial to speed approval timeline By Investing.com - Investing.com South Africa
PDS Biotech Reports 2025 Financial Results and Advances PDS0101 Phase 3 Program with Accelerated Approval Pathway - Minichart
PDS Biotech (NASDAQ: PDSB) details trial progress and $26.7M cash - Stock Titan
Form 10-K PDS Biotechnology Corp For: Dec 31 - StreetInsider
PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap - AlphaStreet
PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings - AlphaStreet
PDSB: Net loss narrowed, clinical trials advanced, and new patents extended exclusivity into the 2040s - TradingView
Bicara Therapeutics 2025 Financial Update - AlphaStreet
Earnings call transcript: PDS Biotech’s Q4 2025 results show improved financial discipline - Investing.com
PDS Biotech amends phase 3 trial to speed approval timeline - Investing.com
PDS Biotechnology: Q4 Earnings Snapshot - marketscreener.com
Phase 3 trial shift and cash update for PDS Biotech (NASDAQ: PDSB) - Stock Titan
PDS Biotech Reports Full Year 2025 Financial Results and - GlobeNewswire
PDS Biotechnology FY 2025 earnings preview - MSN
PDS Biotech redesigns cancer trial to seek faster FDA approval - Stock Titan
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement - Bitget
Published on: 2026-03-28 11:50:07 - baoquankhu1.vn
Aug Breakouts: Whats the analyst consensus on PDS Biotechnology CorporationMarket Trend Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results - The Manila Times
PDS Biotechnology to announce Q4 and full year results on March 30 with clinical and corporate update - Traders Union
PDS Biotech pairs 2025 results with a clinical update on March 30 - Stock Titan
Pds Biotechnology Corp Azioni (PDSB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):